Form 4: Vor Biopharma Inc. Executive Eyal C. Attar Reports Changes in Beneficial Ownership
SEC Form 4 Filing
Eyal C. Attar, Chief Medical Officer of Vor Biopharma Inc., reports the disposal of 1,146 shares of common stock to cover tax obligations related to the settlement of restricted stock units.
Summary
- On August 1, 2024, Eyal C. Attar, the Chief Medical Officer of Vor Biopharma Inc., disposed of 1,146 shares of common stock.
- The transaction was executed to satisfy tax withholding obligations related to the settlement of restricted stock units.
- The shares were disposed of at a price of $0.94 per share.
- Following the transaction, Attar beneficially owns 94,917 shares of Vor Biopharma Inc. common stock.
Sentiment
Score: 5
Explanation: This is a neutral disclosure of a routine transaction. It doesn't indicate positive or negative sentiment about the company's prospects.
Industry Context
Form 4 filings are standard disclosures required by the SEC for insiders of publicly traded companies, providing transparency into their transactions in the company's stock. This filing indicates routine tax-related stock disposal.
Stakeholder Impact
- The transaction has a minimal impact on shareholders as it is a small number of shares being disposed of by an executive to cover tax obligations.
Key Dates
| Date | Description |
|---|---|
| 08/01/2024 | Date of transaction: Disposal of 1,146 shares of common stock. |
| 08/05/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.